Edgestream Partners L.P. Purchases New Shares in West Pharmaceutical Services, Inc. $WST

Edgestream Partners L.P. acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 37,754 shares of the medical instruments supplier’s stock, valued at approximately $8,261,000. Edgestream Partners L.P. owned about 0.05% of West Pharmaceutical Services as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in WST. Vanguard Group Inc. raised its holdings in shares of West Pharmaceutical Services by 0.9% in the second quarter. Vanguard Group Inc. now owns 9,316,804 shares of the medical instruments supplier’s stock valued at $2,038,517,000 after buying an additional 85,083 shares during the last quarter. Artisan Partners Limited Partnership increased its position in West Pharmaceutical Services by 3.3% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,267,319 shares of the medical instruments supplier’s stock valued at $496,089,000 after acquiring an additional 71,836 shares in the last quarter. Durable Capital Partners LP raised its stake in shares of West Pharmaceutical Services by 146.8% in the first quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock worth $352,190,000 after acquiring an additional 935,721 shares during the last quarter. APG Asset Management N.V. grew its stake in shares of West Pharmaceutical Services by 8.7% during the first quarter. APG Asset Management N.V. now owns 1,562,139 shares of the medical instruments supplier’s stock valued at $323,766,000 after purchasing an additional 124,737 shares during the last quarter. Finally, Generation Investment Management LLP bought a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $255,072,000. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

WST has been the subject of several research analyst reports. Barclays boosted their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Monday, October 27th. Rothschild Redb raised West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Morgan Stanley set a $285.00 price target on West Pharmaceutical Services in a report on Monday. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 23rd. Finally, Cowen initiated coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $343.36.

West Pharmaceutical Services Trading Down 1.1%

NYSE WST opened at $274.13 on Tuesday. The stock has a 50-day simple moving average of $271.87 and a 200 day simple moving average of $246.47. The company has a market capitalization of $19.72 billion, a PE ratio of 40.61, a P/E/G ratio of 4.09 and a beta of 1.08. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The company’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.85 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.